Since the first introduction of a genome-wide screening technique, namely cytogenetic analysis of banded metaphase chromosomes, into the analysis of malignant lymphoma in the 1970s the detection of genetic aberrations in neoplastic lymphocytes and their precursors has significantly advanced our understanding of lymphoma biology. Consequently, the identification of recurrent genetic aberrations has fostered biologybased lymphoma classification systems and the detection of such aberrations is increasingly gaining importance in the diagnostic process. The detection of so called primary chromosomal aberrations, which predominately means recurrent chromosomal translocations leading to oncogene activation, is becoming standard in many diagnostic laboratories. Nevertheless, the advent of genome-wide highresolution array-based screening technologies (like array-CGH, SNP-arrays or arraybased gene expression or epigenetic profiling) and the very recent introduction of genome-wide sequencing on the DNAand RNA-level has yielded high-dimensional data which now pose novel challenges for diagnostics and prognostication. On the one hand these technologies provide exciting insights into novel tumorigenic events, commonly deregulated pathways and potentially druggable targets, on the other the overwhelming amount of data require cautious interpretation and clinical evaluation in trials. Moreover, novel genomic markers need to be considered in the light of well established clinical variables. The future integration of novel findings in lymphoma genomics into routine lymphoma care leaves us with several challenging questions, like: What is the leading marker of lymphoma diagnostics? Which kind of genetic diagnostics is indicated? What do genetic factors add to prognostication? Which new therapies can be developed on genomic findings? This introductory lecture aims at reviewing recent developments in lymphoma genomics and epigenomics and at highlighting the importance of (epi)genomics for lymphoma biology, classification, prognostication and treatment.